AuroraA
57 programs · 57 companies
Programs
57
Companies
57
Active Trials
41
Targeting AuroraA
| Drug | Company | Phase | MOA | Indications |
|---|---|---|---|---|
| Motarapivir | GSK | Preclinical | ALLHeart Failure | |
| BAY-8733 | Bayer | Preclinical | PTSD | |
| BNT-8090 | BioNTech | Phase 2 | Ovarian CaParkinson's | |
| ARG-6988 | Argenx | Preclinical | Wet AMD | |
| Semamavacamten | Ideaya Bio | Phase 1/2 | FabryEpilepsy | |
| Cevinaritide | Praxis Precision | Phase 3 | DLBCLCSU | |
| SND-4562 | Syndax | NDA/BLA | MCL | |
| Lisorapivir | Ultragenyx | Approved | Heart FailureUC | |
| CGO-9628 | CG Oncology | Phase 2/3 | CLLFabry | |
| RCK-5227 | Rocket Pharma | Phase 1 | DLBCLDravet | |
| CHA-IIT-687 | Charite Berlin | Phase 1 | AS | |
| UCL-IIT-280 | UCLA Health | Preclinical | Migraine | |
| XTA-1681 | XtalPi | NDA/BLA | DMDOCD | |
| TES-8949 | Tessera Ther | Phase 3 | MigraineObesity | |
| OMG-4087 | Omega Therapeutics | NDA/BLA | PNH | |
| Teralemzoparlimab | Nurix Ther | Phase 2/3 | LNMDS | |
| Tixanaritide | Tonix Pharma | Phase 2/3 | MCLParkinson's | |
| AMP-408 | Ampio Pharma | Phase 1/2 | AMLEndometrial Ca | |
| Datoglumide | NeuBase Therapeutics | Phase 1 | GIST | |
| Motafutibatinib | Verona Pharma | Preclinical | NSCLC | |
| Lisocagene | Compass Inc | Phase 1 | Crohn'sRB | |
| Sotovorutinib | Bioventus | Phase 2/3 | AngelmanCeliac | |
| Sotosacituzumab | Everest Medicines | Phase 2/3 | PTSDUrothelial Ca | |
| Olpatenlimab | Kintor Pharma | Phase 1/2 | PVWM | |
| Surasacituzumab | Sciwind Bio | Phase 3 | SCDCLL | |
| Bemazanubrutinib | Alexion (AZN) | Phase 2/3 | MyelofibrosisIgAN | |
| AIM-9920 | Aimmune | Phase 2 | T2DMM | |
| Doxasertib | Synthorx (Sanofi) | Preclinical | UCTTR Amyloidosis | |
| Lisolemzoparlimab | Sino Biopharma | Approved | EoEHNSCC | |
| Talarasimod | Cellarity | Phase 1/2 | CTCLACC | |
| BBI-3709 | Bridgebio | Phase 1 | RB | |
| Polatapinarof | Vaxcyte | Approved | MG | |
| GEN-IIT-107 | Genethon | Phase 2 | T2D | |
| CCC-2073 | C4 Therapeutics | Phase 1/2 | CTCLNASH | |
| Rimasotorasib | Curocell | Phase 1 | SLEHNSCC | |
| Pemiglumide | Glenmark Pharma | NDA/BLA | MM | |
| Bemazanubrutinib | Dechra Pharma | Approved | WilmsMDD | |
| Gelisacituzumab | Evolva | Phase 1 | Heart Failure | |
| Lisonaritide | ALK-Abello | Phase 1/2 | HSAS | |
| Ribotenlimab | Oasmia | NDA/BLA | MSHCC | |
| BIO-IIT-937 | Bio-Manguinhos | Preclinical | Myelofibrosis | |
| RIC-5834 | Richmond Lab | Phase 2/3 | Alzheimer's | |
| VIN-1694 | Vingroup Biotech | Approved | EpilepsyFSGS | |
| JAM-9461 | Jamjoom Pharma | Phase 2/3 | NarcolepsyBCC | |
| PET-IIT-604 | Peter MacCallum | NDA/BLA | LN | |
| SEV-IIT-475 | Severance Hospital | Approved | LGS | |
| NAT-IIT-211 | Natl Taiwan Univ Hosp | Phase 3 | Hemophilia A | |
| HOS-IIT-835 | Hospital Israelita Einstein | Phase 3 | MS | |
| Terafutibatinib | Intas Pharma | Phase 3 | Breast CaUC | |
| 002-5533 | Shanghai RAAS | Phase 2/3 | NSCLC | |
| Talacagene | Frontline BioSciences | Phase 2/3 | Breast CaNMOSD | |
| Talatuximab | KRKA | Phase 2 | Parkinson'sPsoriasis | |
| BLC-6641 | Bausch + Lomb | Phase 3 | NASHCSU | |
| Kemaderotide | Oragenics | Approved | Endometrial CaAML | |
| Sotovorutinib | IDEXX Laboratories | Phase 1/2 | Melanoma | |
| EWT-919 | Edgewise Therapeutics | Preclinical | MDSCSU | |
| Nidatenlimab | Seer | Phase 1 | NASH |